NewAmsterdam Pharma Company N.V. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments
NewAmsterdam Pharma Company N.V. (NAMS) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments of $0 for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments · last filed 2025-08-06
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for the quarter ending 2025-06-30 was $0.00.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for the quarter ending 2025-03-31 was $0.00.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for the quarter ending 2024-12-31 was $0.00.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for the quarter ending 2024-09-30 was $0.00.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for fiscal 2024 was $0.00.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for fiscal 2023 was $0.00.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for fiscal 2022 was $0.00.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for fiscal 2021 was $0.00.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments 12 month |
|---|---|---|---|---|
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | $0.00 derived: sum of 3 quarters · filed 2025-08-06 | $0.00 derived: sum of 4 quarters · filed 2025-08-06 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2025-05-08 | $0.00 derived: sum of 3 quarters · filed 2025-05-08 | $0.00 derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | $0.00 derived: sum of 3 quarters · filed 2025-08-06 | $0.00 10-K · filed 2025-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-08-06 | $0.00 10-Q · filed 2024-11-06 | $0.00 derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | $0.00 derived: sum of 3 quarters · filed 2025-08-06 | $0.00 derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2025-05-08 | $0.00 derived: sum of 3 quarters · filed 2025-05-08 | $0.00 derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | $0.00 derived: sum of 3 quarters · filed 2025-02-26 | $0.00 10-K · filed 2025-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $0.00 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |